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Among pharmaceutical solids, hydrates are a commonly chosen crystalline form for 
commercialization. Compared to their anhydrous counterparts, hydrates are often more stable 
due to strong hydrogen bonding networks between water and pharmaceutical molecules. 
However, this stability atypically comes with the tradeoff of lower solubility, and research is 
needed to uncover novel pharmaceutical forms displaying both optimal solubility and stability. 
This dissertation focuses on both common and unconventional methods of hydrate crystal 
modification in order better understand limitations of current approaches in the field as well as 
chart promising directions for future research.  
 Polymorphism, the ability of a molecule to pack into multiple crystal forms, can result in 
forms with unique physical and chemical properties. Extensive analysis of crystal forms 
published in the Cambridge Structural Database, however, alludes to an observed low prevalence 
of hydrate polymorphism among known structures, indicating this route is not ideal for hydrate 
modification. Other methods, such as precise control of water available during crystallization, 
can also have an effect on the crystal form achieved. With the antileukemia compound 
mercaptopurine, this method results in the discovery of a hemihydrate crystal form, which 
displays superior solubility and bioavailability compared to the commercially used monohydrate 
form. The hemihydrate form also displays the highest known dehydration temperature for a non-
salt organic molecule reported in the literature (240 °C). Extensive material characterization 
explains the physical basis for these properties, with the hemihydrate water molecules residing in 
electrostatically shielded pockets within the structure.  
 Controlling water present during crystallization of miconazole also allowed for the 
discovery of a novel hemi(hydrogen peroxide) solvate form. Characterization such as 
thermogravimetric analysis, Karl Fisher titration, and 
31
P NMR verify the presence of hydrogen 
peroxide within the structure and X-ray diffraction shows the similar but not isostructural 
packing of the solvate in comparison to the known hemihydrate form. Solid form antifungal 
xix 
 
susceptibility methods are under development to test the efficacy of this hydrogen peroxide 













1.1  Pharmaceutical Solids 
Active Pharmaceutical Ingredients (APIs) are the bioactive components of a drug, which, 
when combined with stabilizers and fillers called excipients, produce the medicines familiar to 
many.1 While medicinal compounds have been used in some context since at least 1100 BCE, 
modern pharmaceutics did not take off until World War II caused a need for an increase in 
research and development of new antibiotics and pain relievers as well as medicines for other 
conditions.2 Overall, many chemical entities may be considered pharmaceuticals, including those 
not initially discovered or marketed as such; nitroglycerine and warfarin were initially used as an 
explosive and rat poison, respectively.2 However, the modern pharmaceutical industry, after the 
creation of the Food and Drug Act in 1906, has seen 1,453 new molecular entities between its 
start and the end of 2013.3 These species are now accepted and maintained by the U.S. Food and 
Drug Administration (FDA), which holds strict requirements on the appropriate qualifications 
and screening an entity must undergo before approval.4,5  
The study of pharmaceutical sciences is composed of many different categories, 
including drug design and analysis, drug action and behavior, and formulations and delivery, all 
of which have a common goal of discovering a novel API for commercialization.6,7 Drug design 
often begins with a target and a screen for molecules effective against that target.2 Rational 
design can be used to modify the molecule until toxicity and efficacy are balanced. Finally, 
formulations are developed to best deliver the dose required, and this is most often in the form of 
a solid, whether as a tablet, capsule, or suspension. Solids are the most common dosage form for 
several reasons.7 Shelf stability is an important property of any pharmaceutical, and where 
liquids are more likely to change concentration or degrade over time, stable solids will retain 
their efficacy for years. Administration as solids is also preferred, for control of a dose compared 
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to measuring out a liquid, and ease of transportation and storage without the risk of spills or 
contamination.7 The work of a solid-state scientist is complex, as properties of the solids will 
cross into many areas of the pharmaceutical industry (Figure 1.1).8 The initial goal for a solid-
state chemist in this field is to modify crystallization or precipitation conditions in order to fully 
characterize all the available solid forms of a molecule for the goal of optimal solubility and 
bioavailability in the body,8 a procedure now required by the FDA.4,5  
 The two broad classes of solids that are generally accepted include crystalline and 
amorphous materials,5,6 where crystalline materials may be broken down into many more 
subclasses (Figure 1.2). Amorphous materials lack any long-range order, and are ideally 
preferred for pharmaceuticals due to their increased solubility. However, the lack of long range 
order is often a kinetically preferred state, and the drive for crystallization makes these forms one 
of the most unstable type of solids.8 Crystalline materials, therefore, are preferred for 
commercialization because their thermodynamic stability provides a reliable set of physical 
properties for the basis of a dosage form. The choice of which crystalline form is used, however, 
can be a complex matter.7  
1.2  Crystalline Properties 
 Anhydrates are the most common type of crystalline material, but are not always the 
preferred choice for pharmaceuticals. Anhydrate forms are often susceptible to absorption of 
water under humid conditions,9 which can cause a change in form during storage. Other options 
include multicomponent systems, such as hydrates or solvates, salts, and cocrystals. Salts are 
also preferable for pharmaceuticals due to the increased solubility of ionic systems in water, and 
their increased thermal stability.7 These too, are susceptible to high humidities however, and may 
become less soluble if water is absorbed into the crystal structure. Hydrates are very common in 
pharmaceuticals, due to the ubiquity of water in the environment, as well as their stability to 
variable humidity conditions, but suffer from a lower solubility in the body.10 Hydrates often 
form because water allows for better packing efficiency of molecules to form crystals,11 and 
therefore, since the molecules are interacting with water in the solid state, the system has less of 
a drive to dissolve and interact with water in a solution phase. This is different from all other 
solvates, where the water solubility is often higher, but so is the toxicity, and therefore very few 
pharmaceuticals are marketed today as any form of organic solvate. Cocrystals, finally, are 
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composed of two neutral solid components, and have emerged in the last few decades as a highly 
modular class of crystalline materials which can be tuned to control specific physical properties 
based on intermolecular interactions in the solid state.12  
 The properties controlled by the solid state can range from melting point, to vibrational 
modes, to dissolution rate (Figure 1.3).13 All of these properties will be controlled by the intra- 
and intermolecular interactions in the solids,14 with the more stable solids usually containing 
stronger electrostatic or hydrogen bonds and the kinetically metastable forms containing weaker 
bonds which are easier to break. Most of these physical properties can be measured with various 
forms of spectroscopy, such as Raman or Infrared, as well as thermal analyses such as 
Differential Scanning Calorimetry (DSC) or Thermogravimetric Analysis (TGA).15,16 It is 
essential, especially for pharmaceuticals, to understand all possible phase transitions from 
changes in temperature, as well as decomposition and melting points of any crystal forms to 
understand the range of storage conditions a final dosage can withstand.   
For pharmaceuticals, dissolution rate and solubility are some of the most important 
physical properties,17,18 and metastable forms tend to show an increased dissolution rate. As with 
amorphous forms, if the metastable form is too unstable, it could potentially convert to the more 
stable form under certain storage conditions, negating its use. Therefore, a proper balance 
between stability and solubility must be achieved when choosing a solid form for 
commercialization.   
 The other important characteristic of pharmaceutical molecules is intestinal permeability, 
which combines with solubility to predict the bioavailability of the drug in the body. Amidon and 
coworkers developed the Biopharmaceutics Classification System in the early 1990s to classify 
pharmaceuticals based on their water solubility and intestinal permeability (Figure 1.4),18 and the 
FDA has adopted this system in their guidance for new and abbreviated drug applications.19 In 
most cases, the permeability of a molecule is determined by the molecular structure of the 
molecule itself, and does not rely on the solid form the molecule dissolved from. Hydrophobic 
molecules, while having lower water solubility, are more likely to permeate the lipophilic 
intestinal membranes, while hydrophilic molecules are exactly the opposite. It has been shown 
that through the inclusion of certain excipients in a dosage form, both the solubility and 
permeability of a molecule can be affected;20-24 however, this modulation is often in the direction 
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of increased solubility through complexation, which has a detrimental effect on the permeability. 
Recently in the literature, researchers have begun considering the permeability of cocrystals,25-30 
and have noticed increased permeability of dissolved cocrystals over that of physical mixtures, 
indicating that some type of physical interaction is carried into solution from the solid that 
provides a benefit for permeability.  
1.3  Polymorphism 
 Polymorphism in pharmaceutical crystals is very common, and results when two or more 
crystalline structures exist that contain the same molecular entities that are arranged differently 
in the solid state (Figure 1.5).31 All crystal types can form polymorphs, whether single 
component anhydrates or any form of multicomponent system, and isolation of polymorphs can 
greatly depend on the conditions used for crystallization.32 Polymorphism has been known since 
the early 1800’s, but has never garnered a comprehensive definition agreed upon by all crystal 
engineers.33 This ambiguity has resulted in many different methods for analysis of polymorphism 
and its prevalence,34-37 leaving researchers with an unknown propensity for how common 
polymorphism is in general.  
 One feature of polymorphic compounds that is widely agreed upon is the effect that 
polymorphic forms can have on the physical properties of a compound. Rearrangement of 
molecular packing in a crystal structure can have a drastic effect on properties,14 just as with 
changes in crystal type. For pharmaceuticals in particular, it is known that changes in 
polymorphic forms will have an effect on the solubility and dissolution rate of the solids.7 As 
mentioned above, higher solubility is desired for pharmaceuticals, as long as it is not at the 
expense of the stability of the form. One of the most recognizable cases where polymorphism 
affected a marketed pharmaceutical is with the medication Ritonavir.38 When the initial solid was 
marketed, there was only one polymorphic form known and therefore commercialized. However, 
after two years on the market, a more stable form II was observed in capsules which greatly 
lowered the oral bioavailability of the drug. The medication had to be temporarily removed from 
the market until this problem could be averted, and highlighted for the community the 
importance of a full polymorph screen of pharmaceuticals before entrance to the market.  
 When considering organic compounds, most molecules that display polymorphism only 
have two structurally characterized forms to date, but there are a few examples of remarkable, 
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highly polymorphic compounds (Figure 1.6). In 2012, the non-steroidal anti-inflammatory drug 
(NSAID) flufenamic acid was shown to display nine different polymorphic forms, with eight of 
these being structurally characterized after growth on polymer surfaces.39 In 2014, it was 
determined that the antidepressant drug aripiprazole also had eight of its ten known polymorphic 
forms structurally characterized, with the last being due to a low temperature phase transition 
from form II.40  While polymorphic prediction is still a growing area, it is important to 
understand that while all compounds may have the potential to exhibit polymorphism, 
crystallization screening and molecular structure may play significant roles in the frequency that 
polymorphism is experimentally observed.  
1.4  Crystalline Hydrates 
 There are necessary distinctions when discussing crystal types in order to separate out 
cocrystals (comprised of two neutral, solid components) and solvates (comprised of one solid 
and one liquid component).41,42 While cocrystals are a newer class of crystalline materials, 
organic solvents have been commonly used in crystallization conditions in the past, and 
depending on the method of crystal growth, solvent molecules may get trapped in the lattice, or 
even contribute to the stability of a growing structure to produce a solvated crystal., The most 
commonly observed solvates are hydrates,  where the solvent is water.10,13 Hydrates are observed 
more frequently than organic solvates, but not just because water is used commonly as a 
crystallization solvent. Many solid forms are also susceptible to absorption of water and may 
convert to hydrates upon storage.37 Due to the abundance of water in the environment, water may 
also absorb into an organic solvent, and get preferentially incorporated into a structure, as the 
vast array of possible hydrogen bonding motifs with water molecules allows for stabilization of 
many molecules into crystalline solids.43  
 While organic solvates are not common for pharmaceuticals due to toxicity issues, 
hydrates are very commonly administered as a marketed form. Since stability is highly desired in 
crystalline solids, hydrates are often optimal due to their strong hydrogen bonding networks, 
allowing for lower energy structures. However, water incorporated into the solid structure 
typically reduces the water solubility of the form, the other critical factor for 
pharmaceuticals.10,37 While a balance between solubility and stability is optimal, the preferred 
form for a marketed pharmaceutical will consist of a hydrate if the anhydrous form is too 
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unstable, as any conversion once tableted will result in an inconsistent dosage of medication. 
Therefore, novel methods of crystal growth and screening are necessary in order to accelerate the 
discovery of stable crystal forms for marketing, whether those still contain water in some fashion 
or another chemical in its place.  
1.5  Organization of thesis 
 This thesis focuses on the modification of crystalline hydrate pharmaceuticals in order to 
increase their dissolution, solubility, and bioavailability. In Chapter 2, the prevalence of organic 
polymorphic compounds in the Cambridge Structural Database44 is assessed in order to 
determine the propensity for hydrates to display polymorphism. Despite their abundance, 
hydrates display one of the lowest percentages of polymorphism among all crystal types. 
Therefore, we have determined other methods of crystallization modification are preferred in 
order to find novel crystal forms of hydrate forming pharmaceuticals.  
Chapter 3 describes the discovery of a novel hemihydrate form of the antileukemia drug, 
mercaptopurine, originally discovered in the 1950’s.45 Crystals of this novel form not only 
exceed the solubility of the commercially used form, but show ~3× the bioavailability of the 
marketed monohydrate. The hemihydrate also shows the highest dehydration temperature of any 
known neutral organic hydrate.46-50 Chapter 4 extends this work with a comprehensive analysis 
to understand the physical route for these improved physical features. It was found that empty 
pockets in the anhydrate structure are able to be filled with water under controlled conditions to 
produce the hemihydrate form, giving a structure which shows optimal solubility as well as 
thermal and shelf stability.  
Chapter 5 explores a new solid form discovery method by replacing the water in a 
hemihydrate form of the antifungal medication miconazole, with structurally similar hydrogen 
peroxide. This method is viable for the use of a topical medication in order to increase the 






1.6  Figures 
 
Figure 1.1. An illustration of fields of the pharmaceutical industry impacted by solid-state 










Figure 1.3. (a) Hydrogen bonding of dasatinib anhydrate molecules. A homodimer is formed 
with N···HN bonding. (b) Hydrogen bonding of dasatinib monohydrate molecules with water. 
The homodimer is broken up by the presence of a water molecule. (c) Raman spectra of the two 








Figure 1.4. Chart showing solubility and permeability qualifications for the four classes in the 
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Survey and Analysis of Crystal Polymorphism in Organic Structures† 
 
2.1.  Introduction 
 Polymorphism is a concept that has been well known within the crystallization field since 
Mitscherlich discovered different crystal forms of the same phosphate salt in the early 1800’s.1 
However, it was not until the late 1960’s that McCrone presented a review on the relevance of 
this concept in the field of pharmaceuticals, where it would eventually become one of the most 
studied topics in solid-state organic chemistry.2 McCrone famously posited that the discovery of 
polymorphs is correlated with the energy and time put into researching a compound.2 We have 
spent the last 15 years in our lab researching crystallization and polymorphism3,4 and indeed, 
polymorphs of many molecules have been isolated in this time,5-9 leading to advancements in the 
understanding of solid-state molecular packing and how variations in packing can affect physical 
properties. We are also not alone in this endeavor; a search for the term “polymorph” in the 
journal Crystal Growth & Design shows that on average, 18% of the research articles and 
communications published in the last 15 years contain this term (Table B.1).a However, funds are 
limited and researcher time is in high demand and so scrutinizing every new organic molecule 
for polymorphism is not a realistic goal. With this obvious constraint, it is important to 
understand the limitations of this research topic and how to utilize what has been previously 
discovered in order to direct future research most efficiently.10 Herein we examine organic 
polymorphs deposited in the Cambridge Structural Database (CSD) to determine the trends in 
prevalence as a function of time and crystal type providing an overview of research activity and 
progress in the field.  
                                                          
† Unpublished work. 
a Searching for this term in Crystal Growth & Design leads to very few false hits involving genetic polymorphism or indeed other 
meanings of the term. See Experimental Methods for more details.  
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The CSD is the most extensive and accessible listing of crystal structures within the 
scientific community, and it serves as the basis for the analysis herein.11 Using this approach will 
underestimate the occurrence of a phenomenon such as polymorphism because many crystalline 
materials are not crystallographically characterized and deposited into this database. For 
example, Stahly showed that solid form screening can lead to many polymorphic forms being 
discovered, albeit for a subset of pharmaceutically relevant compounds whose structures were 
not disclosed.12 In order to choose a more inclusive subset of crystals, the entries available in the 
CSD are analyzed here to make general conclusions based on the relative occurrence of 
polymorphism in organic compounds.  
When a structure is deposited in the CSD, information about the compound is recorded 
such as unit cell parameters, molecular makeup, and the experimental conditions used to solve 
the structure. This can also include other relevant data tags such as the mention of polymorphism 
of the specific chemical entity. However, since the term polymorphism is not always uniformly 
defined, entries are sometimes flagged as polymorphs that are not equivalent in nature.1, 13-15 In 
addition, there is a lack of distinction between structures that represent two forms that can 
coexist under the same conditions, and those solid phases of a compound existing only under 
specific and separate conditions. Practically, this relationship is important because the stability of 
a form directly relates to its properties, such as bioavailability in pharmaceuticals or performance 
in energetic materials.16-20 For this reason, attempts are made herein to distinguish between these 
types of polymorphs in the CSD.  
Building on past efforts involving surveys of subsets of the CSD,1,10,21,22 we sought here 
to be more comprehensive and inclusive in this analysis such that a number of trends can be 
discerned; these trends may be considered as one piece of the puzzle that is crystal 
polymorphism. Sarma and Desiraju conducted a seminal study of polymorphism prevalence, 
where both organic and organometallic single component polymorphs from the CSD were 
analyzed based on carbon content and molecular flexibility.22 Overall, they concluded 
polymorphism to be “essentially a random phenomenon” with molecules of all sizes showing the 
same prevalence for polymorphism at ~3%.22  Cruz-Cabeza et al. analyzed a subset of the 2011 
CSD as well as internal statistics from solid form screens performed at Roche and Eli Lilly for 
the occurrence of polymorphism, and found again that molecular flexibility and size were not 
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correlated with polymorphism, but that “each compound constitutes a new challenge” when 
understanding the phenomenon.10 Through the years, others have also compiled data from 
internal sources or pharmaceutical databases, such as the European Pharmacopoeia or the Merck 
Index but such analyses naturally are biased towards pharmaceutical systems which have been 
screened specifically for polymorphism.12,23 To determine the relative propensity for any organic 
crystal type to display polymorphism, the present study analyzes all organic structures in the 
2015 CSD with 3D coordinates known. Making these results available to scientists interested in 
crystallization for any purpose, beyond just pharmaceuticals, will help to inform all about the 
relative likelihood of encountering polymorphs of a particular crystal type based on past research 
efforts. 
2.2  Results and Discussion 
Figure 2.1 shows that most (75%) of the entries on the list of 4,573 unique polymorphic 
refcodes (Table B.2) identified in the Experimental Methods were confirmed as polymorphic 
compounds (Table B.3). There were, however, a large percentage of compounds with only one 
crystal form characterized (details in Tables B.4 and B.5). In light of van de Streek and 
Motherwell’s 2005 assessment of polymorphic compounds in the CSD,21 we were surprised by 
the number of cases with only one crystal form present and analyzed these instances further. 
Slightly more than 55% of these refcodes do in fact have only one presence in the CSD. In these 
cases, the compounds were most likely flagged as polymorphic due to their associated 
publications mentioning this concept when a second form may have only been characterized by a 
method other than crystallography.24,25 The remaining hits were found to have other entries 
present in the CSD, albeit only by removing the search parameter of having 3D coordinates 
available. This parameter has been chosen in order to only select those compounds with full 
structural proof of polymorphism, and thus these 347 entries are excluded in the overall. 
However, in the remaining few cases where multiple entries were listed with 3D coordinates 
known, they show up on this list because only one entry was flagged as a polymorph. The reason 
some of these polymorphic entries are not flagged upon deposition of the structures in the CSD is 
unknown, but these 61 compounds have been included in the overall list as they do in fact 
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display polymorphism.b The small list of entries in the Other category, which have also been 
excluded from the overall list, is shown in Table B.6.  
When analyzing organic crystalline materials, characterization of physical properties, 
such as solubility or melting, for example, is especially crucial for polymorphs.14,26,27 Property 
measurements should be conducted under comparable conditions, without changes in 
temperature or pressure, to make concrete conclusions about polymorphic differences. It was 
observed that a small group (~10%) of the organic polymorphic compounds were a result of 
changes in structure due to temperature or pressure (Figure 2.1). Due to the complications with 
assessing physical properties of these polymorphs for comparison under the same conditions, we 
have separated these (termed here as Class B) from the rest of the polymorphs (Class A) to show 
the occurrence of this type of polymorphism (see Experimental Methods for details on 
determination of class B polymorphs). However, both classes are included in the comprehensive 
list. The overall list of polymorphic compounds (Table B.3) was broken down further into crystal 
types (single component anhydrates, salts, hydrates, non-hydrated solvates, and cocrystals) as 
shown in Figure 2.1. As expected, anhydrates are the most common crystal type of polymorphic 
compound, with salts as a distant second. For Class B, the salt category is much larger, at 32%, 
than for Class A (14%). In salts, the addition of coulombic attraction/repulsion on top of other 
noncovalent interactions is a differentiating feature. Perhaps, the weaker distance dependence of 
ionic interactions overlaid with interactions much more sensitive to intermolecular distance leads 
to a far greater prevalence of temperature-dependent phase transitions in salts during changes in 
lattice constants. 
To further put the listing of polymorphs into context, the overall occurrence of each type 
of organic crystal was analyzed to compare the number of polymorphic compounds relative to 
the number of organic compounds in general (Figure 2.2). Comparison of the number of 
polymorphic compounds with those considered to be monomorphic in the CSD (only having one 
crystal form characterized) provides a good indication of the relative occurrence of 
polymorphism in each crystal type. While some crystal types are obvious to search for, such as 
anhydrates (one chemical unit), or salts (containing ions), most multicomponent systems are 
more complicated. As per majority opinion of a group of crystal engineering researchers in 2012, 
                                                          
b Three compounds have polymorphic forms of both H and D species, which extends the list to 4,576 unique chemical systems.  
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we have chosen in this study to separate hydrates, solvates, salts, and cocrystals as separate 
multicomponent systems.28 Since there is no qualifier in the CSD to search for solid or liquid 
components, all entries containing two or more chemical units had to be individually examined 
to separate those that contain at least two neutral solid components (at 25 °C and 1 atm) for 
cocrystals from all solvated entries. Starting with all organic entries in the CSD with 3D 
coordinates known, the data are then divided into single component anhydrates and each form of 
multicomponent system. Each search can be further examined to provide the total number of 
refcode families (see Experimental Methods for details) in order to show the number of unique 
compounds in each area. Similar searches were also conducted adding the tag “polymorph”. 
Finally, the previous analysis of the number of polymorphic compounds in each crystal type is 
included. For the multicomponent systems, this is also further broken down into subtypes of each 
group, in order to show the propensity of each subtype in reference to its crystal type.  According 
to the nomenclature of Grothe et. al., “true” crystals of a crystal type refer to structures, for 
example, containing only two ions of a salt or only one compound with water for a hydrate.29  
One area of note is that among multicomponent systems, the true crystal forms are the 
most prevalent for polymorphism in all cases except hydrates, where salt hydrates dominate. 
Ionic systems often display high propensities towards moisture sorption, most likely leading to 
the higher occurrence of salt hydrates than true hydrates. This phenomenon of true crystal 
prevalence was investigated further to determine if the occurrence of crystals with >2 chemical 
components is low for all organics, beyond just polymorphs, but the data do not support this 
suggestion. In fact, over 24,000 unique structures of crystal systems with 3+ components have 
been structurally characterized. Due to the recent focus in literature on cocrystal 
polymorphism,30-32 these data highlight an attractive area for further study in the future to discern 
if there is a physical basis for the low occurrence of polymorphism in systems with more than 
two components.   
The overall percentages of polymorphism for each crystal type were calculated by 
dividing the number of polymorphic compounds by the total organic compounds for that crystal 
type (yellow highlighted values in Figure 2.2). These data give a static picture for 2015, 
compared to other values presented in the past, and show that cocrystals (1.58%), salts (1.36%), 
and anhydrates (1.22%) all display approximately the same percentage of polymorphs, whereas 
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hydrates and other, non-hydrated solvates yield polymorphs with lower incidence (0.63 and 
0.42%, respectively). These percentages can and have changed over time. For hydrates, the low 
incidence is surprising given the ubiquity of water, but for solvates, the origin of the low 
incidence is more readily understood. Solvates are often not sought after, and frequently occur as 
an incidental result of a crystallization, such that searching for additional polymorphs is not 
commonly carried out. The above analysis regarding percentages of polymorphism for each 
crystal type shows that, as of 2015, cocrystals have a higher propensity for polymorphism than 
single components among structurally characterized compounds thus resolving a debate that has 
lingered for some time.10,33 Due to the small difference in these percentages, however, these data 
should continue to be monitored for several more years, a task which is now made 
straightforward because only new structures need to be added to this extensive and scrutinized 
list.   
As mentioned above, several researchers have postulated over the years why they believe 
cocrystals show more or less prevalence for polymorphism than single component systems.10,31,33 
Based on our analysis herein, cocrystals appear now as the most likely crystal type to show 
polymorphism. To determine how this concept has changed over time, the evolution of the 
entries in the CSD was analyzed. One of the first publications to undertake an analysis of 
polymorphism in the CSD also addressed this temporal question.22 In that article, the percentage 
of polymorphs compared to organics was calculated for every year from 1936-1996, albeit only 
for single component systems and with a slightly different set of parameters than those outlined 
in this study. This analysis has been extended here by looking at all polymorphs for the years 
1991-2015 and by dividing the number of polymorphic entries each year by the organic entries in 
that year (Figure 2.3). While this does not take into account the number of unique compounds 
added each year like the earlier data, it does allow for better analysis of literature trends by 
including any structural determinations deposited in the CSD for that year that fit the outlined 
parameters (Tables B.7-2.13, Figures 2.4 and 2.5). The results show that throughout the years, 
the percentage of polymorphic entries in the CSD is constantly decreasing, most likely due to the 
large and increasing number of new crystal structures being deposited each year, which provides 
a large background effect. Sarma and Desiraju suggested that by 1996, this decrease in the 
percentage of polymorphs had already levelled off;22 however it appears from these extended 
data to still be changing. The same decreasing trend is seen when splitting the data into single 
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and multicomponent crystals. However, when looking at specific types of multicomponent 
crystals, the results show some variance. For hydrates, the percentage of polymorphs is 
consistently lower than for all other crystal types, which matches with the above analysis of 
polymorph occurrence based on crystal types. For cocrystals however, the percentage of 
polymorphs has been consistent in the last 20 years, with ~4% of the entries being polymorphic. 
This is reflective of an increase in research activity with regards to cocrystal polymorphism, 
which is likely a result of the rapidly growing field of cocrystallization in general. These data 
stand out from all other crystal types, and further exemplifies why breakdown of polymorphic 
trends by crystal type is a necessary factor to better understand the origins of trends in the 
phenomenon as a whole. 
2.3  Conclusions 
Crystal polymorphism continues to be a very active area of solid-state chemistry research 
and sufficient structural data have been amassed in recent decades to discern general trends in 
the field. The fastest percentage growth in entries is in the area of cocrystal polymorphs whereas 
the related phenomenon of polymorphism in solvates/hydrates remains relatively less frequent. 
These results paint a picture of polymorphism as a pervasive phenomenon albeit one that 
influences different chemical classes at nonuniform rates. The future challenge is to take the 
results of this study and discern a physical basis for the differences in likelihood of isolating and 
structurally characterizing polymorphs of a specific crystal type. Efforts in this direction are 
ongoing. 
2.4  Experimental Methods 
 CSD Searches. All CSD searches were conducted using ConQuest version 1.18. A text 
search for “polymorph” was conducted searching only for organic structures with 3D coordinates 
known.c Previously, van de Streek and Motherwell determined that of all polymorphic 
compounds in the CSD, only a few were not flagged with the “polymorph” tag and worked with 
the CSD to correct omissions, indicating that the keyword search should be sufficient to find 
polymorphic compounds.21 The search described herein yielded 11,909 entries. While this 
                                                          
c The list of polymorphic refcodes from searching version 1.18 of Conquest provides structures deposited up until November of 
2015 (11,909 entries). When searching in version 1.19 of Conquest for structures entered before the Nov. 2016 update, the list 
shows structures deposited up until August of 2015, but also with 192 entries updated after then (11,907 entries). Therefore, it is 
necessary to note which version of Conquest is used when searching for this data.  
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number is substantial, at least two structural forms must be known to characterize a compound as 
polymorphic, and therefore this number is automatically reduced at least in half. However, many 
compounds have multiple entries in the CSD, and therefore the number of unique refcodes, or 
families, may be used to determine the total number of distinct compounds present in the list. In 
the CSD, a refcode consists of a six letter code with the possibility of two numbers following. 
The entries with the same six letter code should constitute the same chemical entity, whether that 
is a single component, a salt, a solvate, or a cocrystal. Herein, the term cocrystal is defined as a 
crystal composed of two molecules that are solids at 25 °C and 1 atm in keeping with common 
usage.28  
Examining the polymorph list for the number of refcode families yields 4,573 distinct 
chemical entities which were then further examined.d An aspect not previously explored by van 
de Streek and Motherwell was the assessment of whether compounds already flagged as 
polymorphs correctly belonged on this list.21 Therefore, polymorphism is confirmed for each 
compound by analyzing the unit cell parameters and simulated powder X-ray diffraction patterns 
exported to Mercury (indicated by van de Streek and Motherwell to be the most reliable 
methods)21 to confirm the existence of multiple structurally characterized forms of the same 
chemical entity.e No attempts are made to correct for temperature differences when assessing 
PXRD patterns, but instead, the associated publications for each deposited structure were 
consulted to determine the situations in which phase transitions were present due to temperature 
or pressure (Class B polymorphs). Figure 2.1 shows the breakdown of these results. 
Table B.2 contains all refcode families from the search for “polymorph”. Green cells 
indicate compounds which have been deemed Class A polymorphs. Pink cells indicate 
compounds which have been deemed Class B polymorphs. Yellow cells indicate compounds 
which had multiple entries listed, but did not have multiple polymorphic forms. Blue cells 
indicate compounds which only had one entry in the list. Orange cells indicate special cases 
which constitute the “other” category shown in Table B.6. Those entries which have a “-D” 
listed after the refcode indicate compounds which had polymorphic forms of a deuterated 
compound. In three cases, there were polymorphs for both the H and D forms of the compound, 
                                                          
d Some cases of conformational polymorphism, where molecules pack in almost identical unit cells but with minor differences, 
can be ambiguous to analyze by this method. In such cases, associated literature was consulted for comparison of multiple forms.  
e Some of these have already been corrected in the 2016 version. The CSD has also been contacted to bring their attention to 
those discrepancies not already addressed.  
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and these are listed separately. The percentages of each group of compounds are shown in Figure 
2.1. 
Table B.3 contains all refcodes for compounds deemed to be polymorphic, whether Class 
A (green) or Class B (pink). The crystal types are listed for each compound. The percentages of 
each type of crystal for each class are shown in Figure 2.1. Refcodes with an asterisk indicate 
those which had only one entry flagged as polymorphs (blue in Table B.2) but were determined 
to be polymorphic compounds having two forms with 3D coordinates determined.   
Entries in Table B.4 are not included in the overall list of polymorphs. The 60 entries in 
blue in Table B.2 that were determined to be polymorphic compounds are not included in Table 
B.4, and were instead integrated into Table B.3 and highlighted with an asterisk. Table B.3 only 
includes compounds that have two structurally characterized entries in a refcode which contain 
3D coordinates. Several entries in Table B.4 have two forms listed as polymorphs, but do not 
have multiple forms with 3D coordinates known, and therefore are not included in Table B.3. In 
this table, PT means phase transition. 
 Crystal Growth & Design Searches. Crystal Growth & Design has been published since 
2001. For polymorphism articles, a search was conducted for that term for the publication range 
of each year, and with the restriction to use print publication date (instead of web publication 
date). Only research articles and rapid communications were considered for this data (reviews, 
editorials, and perspectives were not included). The total number of articles each year was 
determined by counting the number of research articles and rapid communications published in 
each issue, in each year. 
 Details of Other Category. Entries in Table B.6 are in the Other category from the list of 
11,909 entries flagged as polymorphs in the 2015 CSD. There are several reasons why refcodes 
have been included on this list. For some, two forms were observed due to replacement of 
hydrogen with deuterium. If the ability to hydrogen bond is removed or altered in any way, it 
could affect the crystal packing, and this would not fall under the category of polymorphs due to 
a chemical difference in the structures.34 Some molecules were listed as a cocrystal in one 
structure and a salt in another, indicating those two forms would not be polymorphs but instead 
different compounds. Some structures were disputed between authors as to the classification of 
the forms as polymorphs. Most of these refcodes needed to be doubled checked in literature to 
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confirm polymorphism, but were not available due to deposition in the CSD as a private 
communication, giving no experimental data to confirm multiple forms.   
 Details of Polymorphism Tree Searching (Figure 2.2). Searches of the CSD11 detailed 
below were conducted with ConQuest version 1.18 with the restrictions of 3D coordinates 
known and organics only.  
Single components:  
A search was conducted restricting to one chemical unit under Z/Density, and restricting 
entries to those not containing the name ‘hydrate’ or the name ‘solvate’. This gives entries that 
should contain one neutral molecular unit (223,483 hits).   
Multicomponent systems:  
The search for salts involved analysis of any entry that contained two or more chemical 
units under Z/Density, giving 93,927 hits. Adding ‘no ions’ to this search resulted in 47,754, 
indicating that 46,173 hits contained charged species and were considered salts for this case.   
The search for hydrates involved entries containing ‘hydrate’ in the name or a drawing of 
H-O-H to account for cases when water was not explicitly named as a hydrate (26,949 hits). 
A simple search for solvates involved a text search for the word ‘solvate’ which gave 
31,948 hits. However, solvates can also be listed under the term clathrate, a term used to 
designate host guest compounds, but the guest can be a solid or liquid. For this purpose, only 
clathrates that contain liquids are included. A listing of entries with the term clathrate that are not 
already in the solvate list produces 5,444 hits. These are analyzed to remove solid guests and 
3,117 solvates were determined. Added with those in the search for just solvate, the total is 
35,065.  
To determine cocrystals, several searches were conducted: 
A search for 2 chemical units with no ions, no hydrates, and no solvates would be two 
neutral components (11,314 hits). Not every one of these entries shows cocrystals; however, as 
some were clathrates or unlisted solvates, this list needed to be individually sorted through to 
find the number of cocrystal entries in this group (7,080 hits). A search for 3 or more chemical 
units could contain cocrystals plus a solvent, or two solvents and one neutral molecule, as well as 
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salts and/or ionic cocrystals. This search gave 25,667 hits and these were individually analyzed 
to find entries containing at least two neutral components that are solids at room temperature 
(5,712 hits). Added together, this results in 12,792 cocrystal entries.  
Families in each category were determined by finding the number of unique refcodes in 
each list.  
The number of polymorph entries were determined by adding a text search for 
“polymorph” to any of the crystal type searches outlined above.  
The number of polymorph families were determined by finding the number of unique 
refcodes in each polymorph entries list.  
The number of polymorphic compounds are the numbers determined from the outlined 
searches above, with the data presented in Table B.3. Breakdowns for each multicomponent 
crystal type also come from the data in Table B.3, and show the combination multicomponent 















2.5  Figures  
 
 
Figure 2.1. (a) Graphical breakdown of the entries flagged as polymorphs in the CSD. Further 
breakdown of the crystal types (anhydrates, non-hydrated solvate, salt, hydrate, and cocrystal) 











































































































































































































































































































































Figure 2.3. Percentage of polymorphs versus organics in the CSD according to year for specific 
crystal types. Blue markers refer to the total number of polymorph entries/the total number of 
organic entries up until that time. Orange markers refer to the number of polymorph entries/the 











Figure 2.4. Percentage of polymorphs versus organics in the CSD for cocrystals with only 2 





Figure 2.5. Percentage of polymorphs versus organics in the CSD for cocrystals with 3+ 
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